Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity

Inclusion Criteria: * Be 18 years of age or older * Have symptomatic heart failure consistent with NYHA Class III or IV * Have been treated, in the opinion of the Principal Investigator, for at least 12 weeks with an optimized pharmacological regimen, including no substantial dosage titration for the last 4 weeks. This will typically mean that the subject has had (unless intolerant) appropriate doses of angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (β-blockers) and/or aldosterone inhibitors and diuretics. * Have a dilated left ventricular (LV) with an LV end-systolic volume index (LVESVI) of 60 ml/m² and an akinetic or dyskinetic anterior wall * Have an LV ejection fraction less than or equal to 35% * Have an MVO2 of equal to or greater than 10, but equal to or less than 16 ml O2/min/kg * Have demonstrated myocardial infarction without viability on a dobutamine stress echocardiogram in a region considered for surgery. Alternatively, have demonstrated the same physiological feature with gadolinium/magnetic resonance imaging (MRI) procedures or other sophisticated methodology for viability assessment. * Agree to be compliant with the study protocol and willing and able to return for follow-up Exclusion Criteria: * Have had a myocardial infarction within 90 days of consent * Be inotrope or intra-aortic balloon pump (IABP) dependent * Require, in the judgment of the Principal Investigator, cardiac surgery that cannot be deferred for 6 months, such as subjects w…